CureVac GmbH is a biopharmaceutical company specializing in the prophylactic and therapeutic application of messenger RNA (mRNA). CureVac's lead programme is dedicated to the development of active immunotherapies (based on its RNActive® technology) for the treatment of prostate cancer and non-small cell lung cancer. Furthermore, in preclinical studies, CureVac is developing prophylactic vaccines and adjuvants to address infectious diseases.
Type
Private
HQ
Tübingen, DE
Founded
2000
Employees
111 (est)
CureVac was founded in 2000 and is headquartered in Tübingen, DE

Key People at CureVac

Ingmar Hoerr

Ingmar Hoerr

Chief Executive Officer
Mathias Hothum

Mathias Hothum

Baord of Directors
Franz-Werner Haas

Franz-Werner Haas

Chief Corporate Officer
Ulrike Gnad-Vogt

Ulrike Gnad-Vogt

Acting Chief Medical Officer
Mariola Fotin-Mleczek

Mariola Fotin-Mleczek

Acting Chief Scientific Officer
Christof Hettich

Christof Hettich

Baord of Directors

CureVac Locations

Tübingen, DE

CureVac Metrics

CureVac Summary

Founding Date

2000

Total Funding

$387 M

Latest funding size

$29.5 M

Time since last funding

3 months

Investors

We estimate that CureVac's latest funding round in November 2016 was $29.5 M. In total, CureVac has raised $387 M

CureVac Company Life

You may also be interested in